Project Grant R43AG097403
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $506K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92606, USA
Similar Awards
- The National Institute on Aging (NIA) awarded a $154,748 Project Grant under the Aging Research program (CFDA 93.866) to Brigham & Women's Hospital Inc. to develop an ultrasensitive blood-based diagnostic tool for accurately determining the presence and severity of Alzheimer's disease (AD). The project aims to utilize single molecule detection to measure low abundance AD protein biomarkers, particularly phosphorylated tau proteins, in blood extracellular vesicles, which can reflect protein...
- The National Institute on Aging (NIA) awarded a $483,346 Project Grant to Meganano Diagnostics Inc. under the Aging Research Federal Grant Program (CFDA 93.866) for the development of an RT-qPCR assay for early diagnosis of Alzheimer's disease (AD). The project aims to leverage changes in T cell receptor (TCR) clonality in peripheral blood mononuclear cells (PBMCs) as a potential biomarker for early AD detection. Preliminary research by Meganano Diagnostics has demonstrated increased TCR...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $426,555 project grant to Duke University to develop a novel molecular diagnostic technology called "Cascade Amplification by Recycling Trigger Probe" (CARTP) for rapid, multiplex, and ultra-sensitive detection of circulating microRNA (miRNA) biomarkers in clinical plasma samples for the early detection of Alzheimer's disease (AD). The project aims to address the technical...
- The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology...
- This $306,509 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Captis Diagnostics Inc. aims to develop a technology platform for rapid magnetic isolation of neuronal extracellular vesicles (EVs) from blood plasma samples. The goal is to enable the detection of biomarkers for neurological diseases such as Alzheimer's, Parkinson's, and traumatic brain injury through a minimally invasive liquid biopsy approach. Key activities include developing...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Adeptrix Corp. a $499,940 Project Grant on Sep 11, 2025 to develop TAUTRACE, an ultrasensitive immunoassay platform for quantifying distinct molecular forms of the tau protein in cerebrospinal fluid and plasma at femtogram/milliliter levels. This innovative technology enables the detection of single ions, allowing for the quantification of tau proteoforms as critical Alzheimer's disease...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to investigate the presence of Alzheimer's disease (AD) biomarkers in nasally exhaled breath. The $440,000 award to Northwestern University will fund research to test the hypothesis that neural proteins associated with AD, such as tau and beta-amyloid, can be detected and quantified in nasally exhaled breath samples. The 2-year project period runs from...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...
- This federal Project Grant award of $495,731.00, awarded on September 20, 2025 by the National Institute on Aging (CFDA 93.866 Aging Research program), supports the evaluation of Viewmind's ability to detect beta-amyloid and tau burden consistent with Alzheimer's disease in persons with mild cognitive impairment (MCI) using machine learning, virtual reality, and eye-tracking technology. The project aims to develop a non-invasive, cost-effective, and rapid diagnostic tool that can accurately...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $307,538 to Sage Cerebrovascular Diagnostics, Inc. to develop and validate a novel, minimally invasive diagnostic assay to discriminate Alzheimer's disease from vascular dementia. The award aims to: 1) establish the assay's performance characteristics in a clinical laboratory environment, 2) identify the optimal at-home sample collection methodology, and 3) determine the assay's sensitivity...